Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 2/20 | 0.41 |
| ▸ | OXER1 | Q8TDS5 | 2/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.36 |
| ▸ | ITGAV | P06756 | 1/20 | 0.36 |
| ▸ | PLA2G4A | P47712 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | THRA | P10827 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.33 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3685329 | 0.85 | CYP4A11 (0.44) | S1PR1OXER1ITGB3ITGAVPLA2G4A | |
| SCHEMBL3689963 | 0.81 | ITGB3 (0.40) | ITGB3ITGAV | |
| SCHEMBL13509571 | 0.81 | CA12 (0.41) | KMT2AKDM4ECYP1A2CYP3A4CYP2C19 | |
| SCHEMBL3687317 | 0.79 | S1PR1 (0.41) | S1PR1OXER1PLA2G4AKMT2ATHRA | |
| SCHEMBL3684738 | 0.76 | KMT2A (0.39) | KMT2ATP53 | |
| SCHEMBL3681424 | 0.75 | GAA (0.40) | KMT2AKDM4E | |
| SCHEMBL3688516 | 0.74 | TSHR (0.37) | KMT2ACYP1A2CYP2C19TP53 | |
| SCHEMBL16627489 | 0.74 | FPR2 (0.45) | — | |
| SCHEMBL6706690 | 0.71 | PTPN1 (0.44) | KMT2AKDM4ECYP1A2CYP3A4CYP2C19 | |
| SCHEMBL3683044 | 0.70 | NPSR1 (0.42) | ITGB3ITGAVKMT2ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7655641-B2 | Sulfonamide derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2010-02-02 | — | — | US | disclosed |
| US-7655641-B2 | Sulfonamide derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2010-02-02 | — | — | US | disclosed |
| US-7655641-B2 | Sulfonamide derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2010-02-02 | — | — | US | disclosed |
| EP-1597248-B1 | SULFONAMIDE DERIVATIVES AS PPAR MODULATORS | LILLY CO ELI (US) | 2007-12-26 | — | — | EP | disclosed |
| EP-1597248-B1 | SULFONAMIDE DERIVATIVES AS PPAR MODULATORS | LILLY CO ELI (US) | 2007-12-26 | — | — | EP | disclosed |
| US-20060217433-A1 | Sulfonamide derivatives as ppar modulators | ELI LILLY AND COMPANY (US) | 2006-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217433-A1 | Sulfonamide derivatives as ppar modulators | PPARD, PPARA, PPARG | S1PR1 997/4885OXER1 1232/4885ITGB3 4630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.